Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by M. Worm
Vaccination against infectious agents and allergen-specific immunotherapy: A critical analysis.
Allergologie Select, Apr 2023 This is a preview of a remote PDF: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10088876/pdf/ M. Worm, O. Pfaar. , Allergologie Select, pp. 84, DOI: 10.5414/ALX02390E
Vaccination against infectious agents and allergen-specific immunotherapy: A critical analysis.
Dermatology Practical & Conceptual, Apr 2023 This is a preview of a remote PDF: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10088876/pdf/ M. Worm, O. Pfaar. , Dermatology Practical & Conceptual, pp. 84, DOI: 10.5414/ALX02390E
Tralokinumab Plus Topical Corticosteroids in Severe AD
Abstract and Introduction Abstract Background: Patients with severe atopic dermatitis (AD) not controlled with topical therapy have limited treatment options. Ciclosporin A (CSA) is a commonly used, broad immunosuppressant in AD, but treatment with CSA requires monitoring for potentially serious adverse effects. In a previous phase III trial, tralokinumab plus topical corticosteroids (TCS) as needed provided early and sustained improvements in AD signs and symptoms.
Tralokinumab plus topical corticosteroids in adults with severe atopic dermatitis and inadequate response to or intolerance of cyclosporine A: a placebo‐controlled, randomized, Phase 3 clinical trial (ECZTRA 7) - Gutermuth - - British Journal of Dermatolo
ORIGINAL ARTICLE J. Gutermuth, Department of Dermatology, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel (VUB), Brussels, Belgium Joint first authors Search for more papers by this author A.E. Pink, St John’s Institute of Dermatology, NHS Foundation Trust, Guy’s and St Thomas, London, UK Joint first authors Search for more papers by this author M.
Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*
Summary Background Tralokinumab, a fully human monoclonal antibody, specifically neutralizes interleukin‐13, a key cytokine driving peripheral inflammation in atopic dermatitis (AD). In phase II studies, tralokinumab combined with topical corticosteroids provided early and sustained improvements in AD signs and symptoms. Objectives To evaluate the efficacy and safety of tralokinumab monotherapy in adults with moderate‐to‐severe AD who had an inadequate response to topical treatments.
Topical Delgocitinib in Patients With Chronic Hand Eczema
Abstract and Introduction Abstract Background: Management of chronic hand eczema (CHE) remains a challenge; effective topical treatment is limited to corticosteroids. Objectives: To assess the efficacy and safety of a novel, pan-Janus kinase inhibitor (delgocitinib) in patients with CHE. Methods: In this randomized, double-blind, phase IIa study, patients with CHE received delgocitinib ointment 30 mg g−1 or vehicle ointment for 8 weeks.
Randomized controlled trials define shape of dose response for Pollinex Quattro Birch allergoid immunotherapy
Abstract Background The Birch Allergoid, Tyrosine Adsorbate, Monophosphoryl Lipid A (POLLINEX® Quattro Plus 1.0 ml Birch 100%) is an effective, well‐tolerated short course subcutaneous immunotherapy. We performed 2 phase II studies to determine its optimal cumulative dose. Methods The studies were conducted in Germany, Austria and Poland (EudraCT numbers: 2012‐004336‐28 PQBirch203 and 2015‐000984‐15 PQBirch204) using a wide range of cumulative doses.
Anaphylaxis: guidelines from the European Academy of Allergy and Clinical Immunology
Position Paper A. Muraro Corresponding Author Department of Mother and Child Health, Padua General University Hospital, Padua, Italy These authors contributed equally to this work.
Epidemiology of urticaria: a representative cross‐sectional population survey
Dr Torsten Zuberbier, Charité‐Universitätsmedizin Berlin, Allergie‐Centrum‐Charité, Charitéplatz 1, D‐10117 Berlin, GermanyE‐mail: torsten.zuberbier@charite.de Conflict of interest: none declared. PDF PDF Share Summary Aim. To investigate the prevalence of urticaria with a focus on chronic urticaria (CU) in a general German population. Methods. A questionnaire survey was sent to a representative cross‐sectional sample of 13 300 inhabitants of Berlin, Germany, of whom 4093 responded.
Efficacy and safety of topical delgocitinib in patients with chronic hand eczema: data from a randomised, double‐blind, vehicle‐controlled Phase 2a study - Worm - - British Journal of Dermatology - Wiley Online Library
Original Article Efficacy and safety of topical delgocitinib in patients with chronic hand eczema: data from a randomised, double‐blind, vehicle‐controlled Phase 2a study M.
Efficacy and safety of topical delgocitinib in patients with chronic hand eczema: data from a randomized, double‐blind, vehicle‐controlled phase IIa study
Hand eczema is a chronic inflammatory skin disease,1 with varying and potentially interlinked aetiology, such as irritant or allergic contact dermatitis or atopic hand dermatitis.
Allergic contact dermatitis in psoriasis
Summary Recent research suggests that people with the skin disease psoriasis may be at less risk of developing contact dermatitis, which is an eczema‐like reaction in response to the skin coming into contact with an irritant (irritant contact dermatitis) or allergen (allergic contact dermatitis, or ACD). This study looked at the prevalence of ACD specifically, in 2387 people with psoriasis who had been patch tested, compared to 161 981 patch tested people without psoriasis.
The frequency of specific contact allergies is reduced in psoriasis patients
Earlier studies suggested an inverse association between contact allergy and psoriasis, although the results of clinical studies have been inconsistent. Gene‐expression studies in human contact allergy focusing on immune responses revealed nickel being an inducer of Th1/Th17 and some Th22 immune polarization, whereas fragrances were found to promote a Th2‐dominated immune activation.
Randomized controlled trials define shape of dose response for Pollinex Quattro Birch allergoid immunotherapy
The Birch Allergoid, Tyrosine Adsorbate, Monophosphoryl Lipid A (POLLINEX® Quattro Plus 1.0 ml Birch 100%) is an effective, well‐tolerated short course subcutaneous immunotherapy. We performed 2 phase II studies to determine its optimal cumulative dose. The studies were conducted in Germany, Austria and Poland (EudraCT numbers: 2012‐004336‐28 PQBirch203 and 2015‐000984‐15 PQBirch204) using a wide range of cumulative doses.
Pediatric Allergy and Immunology
Division of Clinical and Molecular Allergology, Priority Research Area Asthma and Allergy, Research Center Borstel, Airway Research Center North (ARCN), Member of the German Center for Lung Research, Borstel, Germany Interdisciplinary Allergy Outpatient Clinic, Department of Pneumology, University of Lübeck, Lübeck, GermanySearch for more papers by this author
Factors increasing the risk for a severe reaction in anaphylaxis: An analysis of data from The European Anaphylaxis Registry
Preventive measures to decrease the frequency and intensity of anaphylactic events are essential to provide optimal care for allergic patients. Aggravating factors may trigger or increase the severity of anaphylaxis and therefore need to be recognized and avoided. To identify and prioritize factors associated with an increased risk of developing severe anaphylaxis.
Persistent cow′s milk anaphylaxis from early childhood monitored by IgE and BAT to cow′s and human milk under therapy
Cow's milk allergy affects approximately 2 to 3% of children under 3 years. Allergic reactions often occur at an early onset within the first months of age [1]. In 80 to 85% of the described cases a natural tolerance develops until the age of 5 years. However, a proportion of 1% of adults remain cow's milk allergic, often associated with severe reactions [2].
Impact of systemic alitretinoin treatment on skin barrier gene and protein expression in patients with chronic hand eczema
Chronic hand eczema (CHE) is a common inflammatory skin disease that affects approximately 10% of the population. Systemic alitretinoin has been shown to be effective in patients with CHE who are refractory to topical corticosteroids. To analyse the impact of alitretinoin on the skin barrier genes and protein expression in the skin lesions of patients with CHE. Fifteen patients with CHE were treated with 30 mg daily of alitretinoin for up to 27 weeks.
Epidemiology of urticaria: a representative cross‐sectional population survey
T. Zuberbier, T. Zuberbier Department of Dermatology and Allergy, Allergie-Centrum-Charité, Charité-Universitätsmedizin Berlin, Germany Search for more papers by this author M. Balke, M. Balke Department of Dermatology and Allergy, Allergie-Centrum-Charité, Charité-Universitätsmedizin Berlin, Germany Search for more papers by this author M. Worm, M. Worm Department of Dermatology and Allergy, Allergie-Centrum-Charité, Charité-Universitätsmedizin Berlin, Germany Search for more papers by this author G.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with M.
Contact M., search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack